Company / Capital Expenditures
Idexx Laboratories Capital Expenditures History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Capital Expenditures
$124.7M
FY2025
5-year range
$119.5M / $148.8M
FY2021-FY2025
Trend
+3.1%
vs FY2024
Sector context
#52 of 145
Health Care
What the data says
At $125M, Idexx Laboratories's capital expenditures ranks #52 of 145 in the Health Care sector. Capital Expenditures returned to growth in FY2025 after 2 years of decline, reaching $125M.
Based on SEC 10-K filings.
$125M in FY2025 with a 5-year CAGR of +3.1%.
Declined from $134M to $125M over the past 2 years.
Health Care sector context is included.
Capital Expenditures over time
Growth rates
- 3-Year CAGR
- -5.7%
- 5-Year CAGR
- +3.1%
- 10-Year CAGR
- -
Sector benchmark
#52 of 145 in Health CareTop 36% of 145This company $124.7M Sector average $268.6M
▼
-53.6% below sector average
Key checks
Key Insights
- 5-year CAGR of +3.1%, indicating consistent growth.
- In FY2025, capital expenditures increased 3.1% year-over-year.
- Ranks #52 out of 145 companies in the Health Care sector.
- Peak capital expenditures was recorded in FY2019.
Company context
Key Data Points
- High Piotroski F-Score: 8/9 (strong financial health signals)
- Altman Z-Score 4.60 (safe zone, above 2.9 threshold)
- Strong profit margin: 24.6%
- High earnings quality (cash-backed earnings)
- Strong return on equity: 65.8%
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Capital ExpendituresValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $124.7M | +3.1% |
| FY2024 | $120.9M | -9.5% |
| FY2023 | $133.6M | -10.2% |
| FY2022 | $148.8M | +24.5% |
| FY2021 | $119.5M | +11.8% |
| FY2020 | $107.0M | -31.0% |
| FY2019 | $155.0M | +33.9% |
| FY2018 | $115.8M | +55.6% |
| FY2017 | $74.4M | +14.8% |
| FY2016 | $64.8M | -21.9% |
As of FY2025 · SEC 10-K · Updated Feb 28, 2026